GGrantIndex
← Search

Protocol Review & Monitoring System

$106,075P30FY2020CANIH

Oregon Health & Science University, Portland OR

Investigators

Linked publications, trials & patents

Paper 39764100Paper 39763867Paper 39605535Paper 39435649Paper 39386578Paper 39375962Trial NCT07434128Trial NCT07278440Trial NCT07089940Trial NCT05705492Trial NCT04247425Trial NCT04172493Trial NCT04104139Trial NCT04061980Trial NCT04005690Trial NCT03961672Trial NCT03960177Trial NCT03699995Trial NCT03677531Trial NCT03649880Trial NCT03626285Trial NCT03613259Trial NCT03544125Trial NCT03479268Trial NCT03418025Trial NCT03406013Trial NCT03361436Trial NCT03347617Trial NCT03325166Trial NCT03280277Trial NCT03270059Trial NCT03261180Trial NCT03234309Trial NCT03135782Trial NCT03097588Trial NCT03028935Trial NCT03010358Trial NCT03009201Trial NCT02890979Trial NCT02869412Trial NCT02857218Trial NCT02779283Trial NCT02736617Trial NCT02522715Trial NCT02504359Trial NCT02503358Trial NCT02501759Trial NCT02498951Trial NCT02427841Trial NCT02359097Trial NCT02355262Trial NCT02312557Trial NCT02228265Trial NCT02100189Trial NCT02099864Trial NCT02092324Trial NCT02070705Trial NCT02050919Trial NCT01913015Trial NCT01748942Trial NCT01689987Trial NCT01649505Trial NCT01635413Trial NCT01620216Trial NCT01532687Trial NCT01498978Trial NCT01441882Trial NCT01422408Trial NCT01253642Trial NCT01031953Trial NCT01005914Trial NCT00983398Trial NCT00978562Trial NCT00900302Trial NCT00900068Trial NCT00900055Trial NCT00899795Trial NCT00899522Trial NCT00843167Trial NCT00822848Trial NCT00764517Trial NCT00722072Trial NCT00691652Trial NCT00662103Trial NCT00660543Trial NCT00659126Trial NCT00627276Trial NCT00516542Trial NCT00482274Trial NCT00425386Trial NCT00324324Trial NCT00303849Trial NCT00293475Trial NCT00253721Trial NCT00253643Trial NCT00238433Trial NCT00227682Trial NCT00103038Trial NCT00075387Patent 9279811

Abstract

PROTOCOL REVIEW AND MONITORING SYSTEM ABSTRACT The Knight Cancer Institute Protocol Review and Monitoring System (PRMS) supports the development of a broad and scientifically relevant portfolio of clinical trials. The PRMS works to ensure that cancer patients have access to clinical trials that are rigorous in design, feasible for timely completion, compliant with federal guidelines, deserving of priority, and congruent with the strategic goals of the institute. Two distinct, but critical leadership entities oversee the process: Clinical Research Disease Site Leaders (DSLs) and the Knight PRMS committee. Proposed trials undergo initial prioritization by a DSL to assess scientific merit, alignment with the Institute and disease site goals, available resources, feasibility for completion within specified timeframe, and fit within a disease-level portfolio. In the second-step of the process, the PRMS reviews for relevance of the scientific question, soundness of the design, feasibility to conduct the trial, and ability of the trial to meet an unmet need within the disease trial portfolio. Eligible protocols receive a twice yearly scientific progress evaluation by the PRMS to ensure accrual is on target. In addition, scientific relevance is evaluated for trials open to accrual beyond 5 years. The PRMS has full authority to enact the scientific progress evaluation determination. Personnel in the Knight Clinical Research Quality and Administration group provide administrative support for PRMS, which acts independent of the OHSU Institutional Review Board (IRB) and the Knight Data and Safety Monitoring Committee (DSMC).

View original record on NIH RePORTER →